BMN-351

N/A

Report date: 2026/05/09 20:00:18
NME

Base Information

Drug NameBMN-351
Drug Alias NameBMN-351BMN 351
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionDystrophin expression stimulantsRNA interference
TargetsDystrophin
Therapy Area/IndicationsMuscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaNetherlandsItaly +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBiomarin Pharmaceutical Inc
China Registration ClassN/A

Develop Information

Active CompaniesBiomarin Pharmaceutical Inc
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophy, Duchenne
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A